Hydrochloric Acid

Hydrochloric Acid

SCHEMBL9901410

Cl.N#CCCCN1C=CN(CCCC#N)C1

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CA2 known ✓ P00918 1/20 0.30
MAPT P10636 1/20 0.39
ALDH1A1 P00352 2/20 0.36
PKM P14618 1/20 0.36
TSHR P16473 2/20 0.33
POLB P06746 2/20 0.32
CSNK2A1 P68400 1/20 0.32
LOX P28300 1/20 0.31
LOXL3 P58215 1/20 0.31
LOXL2 Q9Y4K0 1/20 0.31
TDP1 Q9NUW8 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
CA9 Q16790 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9942137 0.98 MAPT (0.40) MAPTALDH1A1PKMTSHRPOLB
SCHEMBL28841371 0.93 ALDH1A1 (0.39) MAPTALDH1A1PKMTSHRPOLB
Hydrochloric Acid SCHEMBL2229191 0.88 MAPT (0.34) MAPTALDH1A1PKMTSHR
SCHEMBL4393719 0.83 NPSR1 (0.38) MAPTALDH1A1
SCHEMBL28176782 0.79 MAPT (0.42) MAPTALDH1A1PKMTSHRCSNK2A1
SCHEMBL28204342 0.78 MAPT (0.31) MAPT
Bromide SCHEMBL9547368 0.77 MAPT (0.40) MAPTTSHR
SCHEMBL28179977 0.76 ALDH1A1 (0.39) ALDH1A1PKMPOLBSMN1; SMN2
Hydrochloric Acid SCHEMBL28986348 0.74 MAPT (0.33) MAPTALDH1A1PKM
SCHEMBL12469758 0.71 ALDH1A1 (0.39) ALDH1A1PKMPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3470493-B1 COMPOSITIONS COMPRISING LATENT HEAT STORAGE MATERIALS PHASE CHANGE ENERGY SOLUTIONS INC (US) 2024-05-15 EP claimed
WO-2024081696-A2 COMPOSITIONS CONTAINING PHASE CHANGE MATERIALS, METHODS FOR FORMING OBJECTS USING THE SAME, AND METHOD FOR USING THE SAME PHASE CHANGE ENERGY SOLUTIONS, INC. (US) 2024-04-18 WO claimed
US-10907080-B2 Compositions comprising latent heat storage materials and methods of making the same PHASE CHANGE ENERGY SOLUTIONS, INC. (US) 2021-02-02 US claimed
US-10745604-B2 Compositions comprising phase change materials and methods of making the same PHASE CHANGE ENERGY SOLUTIONS, INC. (US) 2020-08-18 US claimed
EP-3372653-B1 COMPOSITIONS COMPRISING PHASE CHANGE MATERIALS PHASE CHANGE ENERGY SOLUTIONS INC (US) 2020-07-29 EP claimed
EP-3470493-A1 COMPOSITIONS COMPRISING LATENT HEAT STORAGE MATERIALS Phase Change Energy Solutions, Inc. (US) 2019-04-17 EP claimed
EP-3372653-A1 COMPOSITIONS COMPRISING PHASE CHANGE MATERIALS Phase Change Energy Solutions, Inc. (US) 2018-09-12 EP claimed
US-20180148621-A1 Compositions Comprising Phase Change Materials and Methods of Making the Same PHASE CHANGE ENERGY SOLUTIONS, INC. 2018-05-31 US claimed
US-20180112114-A1 Compositions Comprising Latent Heat Storage Materials and Methods of Making the Same PHASE CHANGE ENERGY SOLUTIONS, INC. 2018-04-26 US claimed
US-12595403-B2 Thermal energy storage compositions and methods of using the same PHASE CHANGE ENERGY SOLUTIONS, INC. (US) 2026-04-07 US disclosed
US-20250243396-A1 COMPOSITIONS COMPRISING PHASE CHANGE MATERIALS AND METHODS OF MAKING THE SAME PHASE CHANGE ENERGY SOLUTIONS INC (US) 2025-07-31 US disclosed
US-12372289-B2 Temperature control cart for a payload VESTURE LLC (US) 2025-07-29 US disclosed
WO-2025090830-A1 PHASE CHANGE MATERIALS, COMPOSITIONS COMPRISING PHASE CHANGE MATERIALS, AND METHODS OF MAKING THE SAME PHASE CHANGE ENERGY SOLUTIONS, INC. (US) 2025-05-01 WO disclosed
US-12275886-B2 Compositions comprising phase change materials and methods of making the same PHASE CHANGE ENERGY SOLUTIONS, INC. (US) 2025-04-15 US disclosed
US-20150340168-A1 ELECTROLYTIC SOLUTION FOR ELECTRIC DOUBLE-LAYER CAPACITOR, AND ELECTRIC DOUBLE-LAYER CAPACITOR TOHOKU UNIVERSITY (JP) 2015-11-26 US disclosed
US-20140339460-A1 COMPOSITIONS COMPRISING PHASE CHANGE MATERIALS AND METHODS OF MAKING THE SAME PHASE CHANGE ENERGY SOLUTIONS, INC. 2014-11-20 US disclosed
US-20140319410-A1 COMPOSITIONS COMPRISING LATENT HEAT STORAGE MATERIALS AND METHODS OF MAKING THE SAME PHASE CHANGE ENERGY SOLUTIONS, INC. 2014-10-30 US disclosed
US-20140005415-A1 IMMOBILIZATION OF IONIC LIQUIDS VIA MECHNOCHEMICAL INTERCALATION IN LAYERED MATERIALS TEXAS STATE UNIVERSITY-SAN MARCOS (US) 2014-01-02 US disclosed
WO-2013191297-A1 ELECTROLYTIC SOLUTION FOR ELECTRIC DOUBLE-LAYER CAPACITOR, AND ELECTRIC DOUBLE-LAYER CAPACITOR イデア・インターナショナル株式会社 (JP) 2013-12-27 WO disclosed
WO-2012078783-A2 IMMOBILIZATION OF IONIC LIQUIDS VIA MECHNOCHEMICAL INTERCALATION IN LAYERED MATERIALS TEXAS STATE UNIVERSITY-SAN MARCOS (US) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595403-B2 Thermal energy storage compositions and methods of using the same ATM, CHEK2, MUC1 CA2 31/4885MAPT 110/4885ALDH1A1 2616/4885
US-20140005415-A1 IMMOBILIZATION OF IONIC LIQUIDS VIA MECHNOCHEMICAL INTERCALATION IN LAYERED MATERIALS CALCOCO2, MCOLN2, MECP2 CA2 198/4885MAPT 4116/4885ALDH1A1 4082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.